Intratumor BRAF V600E Heterogeneity and Kinase Inhibitors in the Treatment of Thyroid Cancer: A Call for Participation
Author:
- 1 April 2013
- journal article
- letter
- Published by SAGE Publications in Thyroid®
- Vol. 23 (4) , 517-519
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Sorafenib in advanced iodine‐refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG‐PETClinical Endocrinology, 2012
- Unusual Short-Term Complete Response to Two Regimens of Cytotoxic Chemotherapy in a Patient with Poorly Differentiated Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2012
- SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2Journal of Experimental Medicine, 2012
- Cytotoxic Chemotherapy for Differentiated Thyroid CarcinomaClinical Oncology, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK PathwayJournal of Biological Chemistry, 2003
- Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude MiceThyroid®, 2002
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH StimulationThe Journal of Clinical Endocrinology & Metabolism, 2002